Juniper Biosciences Appoints Renowned Radiopharmaceutical Expert Jason S. Lewis, Ph.D. as Chair of Newly Formed Scientific Advisory Board
Juniper Biosciences announced the launch of its Scientific Advisory Board and appointed Jason S. Lewis, Ph.D., as its inaugural Chair to help guide the development of its precision oncology pipeline.
Read more
Juniper Biosciences Announces Strategic Collaboration with leading global cancer center on F-MISO (JBS-003)
Juniper Biosciences today announced a strategic licensing agreement with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the development of JBS-003 (18F-fluoromisonidazole, or FMISO)...
Read more
Upsized and Oversubscribed Seed Round Completed at $40 Million
Juniper Biosciences LLC today announced the closing of an oversubscribed and upsized $40 million seed financing through its parent company, Juniper Radiopharma LLC, co-led by NovaCapital, several high-net-worth individuals, and members of the Club Degli Investitori.
Read more